stocks of Sarepta Therapeutics rose nearly 27 percent Wednesday after announcing the meals and Drugadministration is delaying its evaluate of a key drug made through the company. The FDA notified Sarepta that “they are persevering with their evaluation and internal
res of Sarepta Therapeutics nearly halved on Thursday after the meals and Drug management maintained its “poor” outlook on the employer‘s drug for an extraordinary muscle-wasting ailment. Sarepta stock closed down more than forty four percentage. Sarepta is seeking out